To establish parameters associated with therapeutic success in gestational diabetics treated with glyburide.
INTRODUCTION
Gestational diabetes mellitus (GDM) affects 3 to 8% of pregnancies and has been associated with increased fetal macrosomia, operative delivery, and birth trauma. 1 Although the data are conflicting as to whether excellent maternal glycemic control reduces the rates of these complications, 1 a goal of medical therapy for women with GDM who cannot be managed on dietary therapy alone (Class A 2 gestational diabetics), is to safely maintain euglycemia. In conjunction with dietary therapy, the mainstay of medical management for these women has been insulin. Oral hypoglycemic agents, utilized extensively in the nonpregnant population, have not been recommended in pregnancy due to their potentially adverse fetal effects. [2] [3] [4] These adverse effects, however, were noted in studies investigating first-generation sulfonylureas. Subsequent in vitro and in vivo studies have shown that glyburide, a secondgeneration sulfonylurea, minimally crosses the placenta. [5] [6] [7] A recent randomized trial conducted by Langer et al. 7 comparing insulin with glyburide in women with GDM demonstrated no detectable levels of glyburide in the cord serum of the group managed with glyburide. No difference in maternal and fetal outcomes were noted between the insulin and glyburide groups. 7 In the study by Langer et al., the insulin and glyburide groups achieved equivalent glycemic control. However, of the 201 women randomized to receive glyburide, 36 (18%) did not achieve optimal blood glucose values, and eight (4%) were discontinued off of glyburide and switched to insulin. 7 Although glyburide offers an inexpensive and less invasive alternative to insulin therapy for GDM, this study highlights the fact that it does not achieve adequate glycemic control in some patients. It is therefore important that clinicians are able to predict which patients with GDM will attain adequate therapy on glyburide with good accuracy and precision in order to avoid delays in achieving euglycemia. Additionally, an algorithm that could predict glyburide success or failure for patients with GDM could help physicians who practice in areas remote from referral centers to feel more comfortable in treating patients who fall within the algorithm, thus reducing the number of patients they would have to refer for management.
The objective of this trial is to investigate the failure rate of glyburide therapy in maintaining target maternal blood glucose levels and to establish specific criteria that can predict the success of glyburide therapy.
MATERIAL AND METHODS
From November 1, 2000 to January 31, 2002, all women in the UCSD Diabetes in Pregnancy clinic with GDM between 13 and 38 weeks of gestation who failed to maintain target levels of maternal glucose levels after 1 week of dietary therapy were offered the option of either glyburide or insulin adjunctive therapy. The UCSD institutional review board approved this protocol.
All women attending the clinic were screened with a 1 hour, 50 g oral glucose challenge. If the women had no risk factors for GDM, they were screened at the standard gestational age of 24 to 28 weeks. Criteria for screening patients earlier than 24 weeks included obesity, history of diabetes in the immediate family and a previous pregnancy complicated by GDM. These women were screened shortly after they presented for their first prenatal visit, with the earliest presentation at 5 weeks and the latest at 37 weeks. All previously diagnosed pregestational diabetics were excluded from the study. Women with plasma glucose concentrations between 140 and 200 mg/dl on the 1-hour 50 g oral glucose challenge underwent a 100 g oral glucose-tolerance test. GDM was diagnosed if the plasma glucose concentration from the 1-hour, 50 g oral glucose challenge was greater than 200 mg/dl or if two or more of the 100 g oral glucose-tolerance test values were abnormal using Carpenter and Coustan's criteria. 8 Upon diagnosis of gestational diabetes, patients were enrolled into a class and taught dietary therapy and capillary glucose monitoring by a certified diabetic educator utilizing the California Diabetes and Pregnancy Program's Sweet Success: Guidelines for Care. 9 Dietary recommendations included three meals and four snacks daily, of which 40 to 45% of the total calories were comprised of carbohydrates. The targeted total weight gain for the pregnancy according to the Sweet Success protocol was 25 to 35 lbs for a BMI of 19.8 to 24.9 kg/m 2 , 15 to 25 lbs for a BMI of 25.0 to 29.0 kg/m 2 , and around 15 lbs for a BMI greater than 29.0 kg/m 2 . Individual nutritional counseling by both the diabetic nurse educator and nutritionist occurred during the 1-week follow-up visit and periodically thereafter as clinically indicated. Capillary blood glucose monitoring was prescribed four times daily: morning fasting blood sugars (FBS) and 1-hour postprandial blood sugars after breakfast, lunch, and dinner. Periodic correlation of the blood glucose log with the values in the glucometer's memory was performed to assess accurate reporting of blood sugars.
At least 1 week of capillary glucose monitoring was obtained on dietary therapy prior to the initiation of medical management. Failure of dietary therapy was defined as at least 20% of the weekly FBS greater than 90 mg/dl and 1-hour postprandial values greater than 130 mg/dl. All women who failed to maintain the desired glycemic control on dietary therapy between 13 and 38 weeks of gestation were enrolled into the protocol.
The known benefits and risks of both insulin and glyburide were reviewed with each patient by the same doctor and included the fact that glyburide is not approved for use in pregnancy by the FDA. The individual was then given the choice of the type of medical therapy they desired. Women who chose glyburide were started on a dose of 2.5 to 5.0 mg per day, and that dose was increased in 2. Patients who failed glyburide therapy were discontinued off of glyburide and switched to insulin, although some patients continued glyburide and added insulin to avoid the delays in achieving euglycemia associated with the transition from glyburide to insulin alone. For those who discontinued glyburide, insulin was given subcutaneously three times a day according to the following scale: 1 to 18 weeks gestation F 0.7 U/kg, 18 to 26 weeks gestation F 0.8 U/kg, 26 to 36 weeks gestation F 0.9 U/kg, and 36 to 40 weeks gestation F 1.0 U/kg. For those who continued glyburide and added insulin, the amount of insulin was adjusted every 2 weeks to maintain euglycemia.
Demographic data, pertinent medical and obstetrical history, glucose tolerance test results, the four-time daily glucose values, and the delivery and neonatal outcomes were recorded in a data sheet. All patients were routinely screened with an ultrasound to assess growth. If they were diagnosed with GDM later than 24 weeks, they received a growth scan at 36 to 37 weeks. Those diagnosed with GDM prior to 24 weeks received growth scans at both 30 to 32 and 36 to 37 weeks. Macrosomia was defined as a birth weight of greater than 4000 g as estimated by ultrasound. The decision to allow a trial of labor or proceed directly to cesarean section without a trial of labor for the indication of macrosomia was left to the attending individual's discretion. Any maneuvers to deliver the anterior shoulder of an infant other than downward traction and episiotomy were recorded as a shoulder dystocia. All infants had serial blood glucose values every 15 to 30 min after birth for the first 2 hours, then before the first two to three meals. Neonatal hypoglycemia was diagnosed if one of those values was less than 40 mg/dl. Other neonatal metabolic parameters were obtained as clinically indicated. In regards to neonatal outcomes, the following definitions were used: hyperbilirubinemia if the serum bilirubin concentration was greater than 15 mg/dl, polycythemia if the hematocrit was above 60%, and hypocalcemia if the serum calcium concentration was below 8.0 mg/dl.
We performed a post hoc power analysis to determine the ability of the samples in the study to detect significant differences in the outcome variables of interest. Considering maternal and neonatal demographic variables, the study was able to detect differences in proportions or mean values of 8 to 12%, with an 80% power, a ¼ 0.05.
For statistical analysis, w 2 tests were used to analyze categorical data and Student's t-tests for continuous data and the Fisher's exact p-values were obtained using SPSS 10.0 (SPSS Inc., Chicago, IL). A receiver-operator curve was utilized to find the cut-points with the greatest sensitivity and specificity for the criteria that were found to aid in predicting glyburide success.
RESULTS
Between November 1, 2000 and January 31, 2002, 69 patients with GDM failed dietary therapy and required medical management. All 69 patients (100%) offered either glyburide or insulin for the medical management of their hyperglycemia opted for glyburide. In all, 13 of the 69 women on glyburide (18.8%) failed to achieve appropriate glycemic control (greater than 20% of FBS >90 mg/dl and 1-hour postprandial values >130 mg/dl) on maximum dose glyburide and had to have insulin added or be switched to insulin. Table 1 compares the demographic data between the glyburide failure and the glyburide success groups. The ethnicity of our study group was predominately Hispanic (87%). There was no difference in ethnicity, enrollment weight, parity, family history of diabetes, previous pregnancies complicated with gestational diabetes, and 1 and 3-hour glucose tolerance test results between the two groups. In all, 64 of the 69 patients enrolled into the study had complete capillary blood glucose values available for analysis. The mean FBS and 1-hour postprandial values were different between the glyburide failure and success groups both prior to and during glyburide treatment. In the 1-week period on dietary therapy prior to the initiation of glyburide, the mean FBS for the glyburide failure group was 126 versus 101 mg/dl in the glyburide success group (p<0.001). The mean 1-hour postprandial values were 157 versus 131 mg/dl, respectively (p<0.001). Similarly, the mean FBS for the glyburide failure group during glyburide treatment was 126 versus 101 mg/dl in the glyburide success group (p<0.001). The mean 1-hour postprandial values during glyburide treatment were 157 versus 131 mg/dl, respectively (p<0.001). These findings are summarized in Table 2 . Table 3 compares the delivery and neonatal outcomes between the glyburide failure and success groups. No significant differences were noted. The Cesarean section rate was 38 and 34%, respectively. The macrosomia rate was 15 and 18%, respectively. None of the Cesarean sections in the glyburide failure group were performed for macrosomia. There were no shoulder dystocias in the glyburide failure group, and three (5%) were documented in the glyburide success group. In regard to neonatal outcomes, no infant in the glyburide failure group and one infant in the glyburide success group developed hypoglycemia. One of the three infants who developed hyperbilirubinemia was in the glyburide failure group. One intrauterine fetal demise occurred at 28 weeks of gestation in the glyburide success group due to multiple true knots in the umbilical cord.
Criteria for predicting glyburide success were established. Utilizing the gestational age at the time of dietary failure and the mean FBS and 1-hour postprandial blood glucose values over the 1-week period in which the patient failed dietary therapy, various cut-points were assessed using a receiver-operator curve in order to maximize the sensitivity for prediction of success with the least decrease in specificity. The results of the receiver-operator curve gave the following criteria: (1) dietary therapy failure after 30 weeks of gestation, and (2) dietary failure at less than 30 weeks with a mean FBS less than or equal to 110 mg/dl and mean 1-hour postprandial blood glucose values less than or equal to 140 mg/dl during the 1-week period of time in which dietary failure occurred. Using the above criteria, glyburide success was predicted with a sensitivity of 98% and specificity of 65%, and a positive predictive value of 89% and a negative predictive value of 92%. Table 4 illustrates how well these criteria would have predicted glyburide success or failure had they been applied to our population before treatment (p<0.001).
COMMENTS
We found that all patients opt for oral hypoglycemic therapy when given a choice between glyburide and insulin. The convenience of administration of glyburide compared to insulin probably contributed to this universal acceptance.
The rate of failure of glyburide treatment to maintain desired glycemic control necessitating a switch to or the addition of insulin was 18.8% in our patient population. This is over four times the rate of glyburide failure that required switching to insulin reported by Langer et al. 7 However, 18% of patients in that study who received glyburide were outside the desired range of glycemic control. 7 The majority of these 18% were managed without insulin, although Langer does not state why. Of interest is the fact that in addition to patients who failed dietary therapy, Langer also started some patients on medical therapy without a trial on dietary therapy if they had a FBS between 95 and 140 mg/dl on the day of their 100 g oral glucose-tolerance test. In contrast, we gave every patient at least a 1-week trial on dietary therapy. Had we used Langer's additional criteria for initiating medical therapy as well as the dietary failure criteria described in the Materials and Methods section of our paper, we might have had more patients started on glyburide therapy, although the effect this would have had on the failure rate in this study is difficult to predict. It is also important to note that our criteria for acceptable glycemic control were not as strict as that used by Langer. Whereas Langer declared glyburide failure for FBS greater than 90 mg/dl and 1-hour postprandial sugars greater than 120 mg/dl over a 2-week period on maximum dose glyburide (20 mg/d), we declared glyburide failure for FBS greater than 90 mg/dl and 1-hour postprandial sugars greater than 130 mg/dl on maximum dose glyburide (10 mg b.i.d.) over 1 week. Our failure rate may have therefore been even higher had we applied Langer's more rigorous criteria for glyburide failure. We also recognize that our criteria for acceptable glycemic control in deciding when to begin medical therapy and when to declare glyburide failure may be more stringent than what some perinatologists may use. Nevertheless, both studies show that glyburide is ineffective in maintaining desired glycemic control in at least greater than one-sixth of patients.
The importance of differentiating between groups of patients who are likely to do well on glyburide is illustrated in our study. The patients who succeeded on glyburide therapy maintained their blood glucose values within the desired range while on the medication. In contrast, the patients who were destined to fail glyburide therapy had significantly higher fasting and 1-hour postprandial blood glucose values and were outside the desired range while on glyburide therapy. The mean duration of glyburide treatment in the glyburide failure group was 6.8 weeks. Thus, it took over a month and a half for those patients to declare themselves as a glyburide failure. These patients never achieved a stable control of their blood sugars and were on the verge of failure virtually the entire time they were on glyburide. A criterion to predict glyburide success would have been useful to avoid the delays in maintaining euglycemia that occurred in the glyburide failure group. Although our study did not show any difference in maternal or neonatal outcomes between the two groups, the study may have lacked sufficient power. We noted that the two most significant indicators of glyburide success were gestational age upon dietary therapy failure and the mean blood glucose values prior to initiating glyburide. These two parameters are useful because that information should be readily available to providers who are considering starting glyburide therapy in women with gestational diabetes. The criteria providing the highest sensitivity for glyburide success with minimal impact on specificity were as follows: (1) women who fail dietary therapy after 30 weeks, and (2) those women who fail dietary therapy before 30 weeks but have mean FBS less than or equal to 110 mg/ dl and mean 1-hour postprandial blood glucoses less than or equal to 140 mg/dl. These criteria are 98% sensitive and 65% specific for predicting glyburide therapeutic success.
In the appropriately screened patient population, glyburide therapy represents a convenient and inexpensive alternative to insulin. In clinical practice, these criteria will enable practitioners z Prematurity defined as less than 37 weeks gestation at delivery. Macrosomia defined as birth weight greater than or equal to 4000 g. y Fetal anomaly was achondroplasia. w p-values were calculated by a two-tailed t-test with equal variance assumed. who are remote from referral centers to confidently manage women who fulfill the criteria, thus referring only a fraction of the patients who require more intensive therapy. This protocol may also allow for refocusing of resources from insulin care to other pertinent areas such as dietary and compliance issues for those women.
There are several deficiencies of this study that should be considered. The criteria for oral therapy success in this study were established from the cohort analysis. A prospective trial utilizing these criteria is required to confirm our findings. Secondly, although we excluded known pregestational diabetics, we did not attempt to screen out unrecognized pregestational diabetics that may have been hidden in those women diagnosed early in pregnancy. Any future studies that attempt to confirm our findings will have to take this into account. Additionally, our patient population is comprised primarily of Hispanic women, and the findings may not be as applicable to other ethnicities. Finally, the number of patients is probably inadequate to detect differences in obstetrical and neonatal outcome between the two groups.
To conclude, our study indicates that women clearly preferred glyburide therapy over insulin. However, we have shown that over one-sixth of those women will fail to achieve desired glycemic control and will require insulin therapy. We have developed criteria that are helpful in predicting glyburide therapeutic success in women with gestational diabetes.
